Early Spondyloarthritis

Rheumatic Disease Clinics of North America

Volumn 38, Issue 2, 2012, Pages 387-403

  Poddubnyy, Denis ^a   Rudwaleit, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ankylosing spondylitis; ASAS; Early diagnosis; Spondyloarthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY; BACKACHE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; DELAYED DIAGNOSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG INDICATION; EARLY DIAGNOSIS; EUROPEAN LEAGUE AGAINST RHEUMATISM; HEALTH PROGRAM; HUMAN; LABORATORY TEST; MEDICAL SOCIETY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATIENT REFERRAL; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SACROILIAC JOINT; SACROILIITIS; SPONDYLARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DELAYED DIAGNOSIS; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; SACROILIAC JOINT; SPINE; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 84864007544     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.04.007     Document Type: Review

References (62)

1. Rudwaleit M., Khan M.A., Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum 2005, 52(4):1000-1008.
2. Poddubnyy D., Rudwaleit M., Haibel H., et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011, 70(8):1369-1374.
3. Rudwaleit M., Haibel H., Baraliakos X., et al. The early disease stage in axial spondyloarthritis: results from the German spondyloarthritis inception cohort. Arthritis Rheum 2009, 60(3):717-727.
4. Braun J., Bollow M., Remlinger G., et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998, 41(1):58-67.
5. Helmick C.G., Felson D.T., Lawrence R.C., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58(1):15-25.
6. Gofton J.P., Robinson H.S., Trueman G.E. Ankylosing spondylitis in a Canadian Indian population. Ann Rheum Dis 1966, 25(6):525-527.
7. van der Linden S.M., Valkenburg H.A., de Jongh B.M., et al. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984, 27(3):241-249.
8. Khan M.A. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995, 7(4):263-269.
9. Hukuda S., Minami M., Saito T., et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001, 28(3):554-559.
10. Belachew D.A., Sandu N., Schaller B., et al. Ankylosing spondylitis in sub-Saharan Africa. Postgrad Med J 2009, 85(1005):353-357.
11. Zink A., Braun J., Listing J., et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000, 27(3):613-622.
12. Feldtkeller E., Bruckel J., Khan M.A. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 2000, 12(4):239-247.
13. Feldtkeller E., Khan M.A., van der Heijde D., et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003, 23(2):61-66.
14. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27(4):361-368.
15. Underwood M.R., Dawes P. Inflammatory back pain in primary care. Br J Rheumatol 1995, 34(11):1074-1077.
16. Braun J., van den Berg R., Baraliakos X., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70(6):896-904.
17. van der Heijde D., Sieper J., Maksymowych W.P., et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011, 70(6):905-908.
18. Rudwaleit M., Claudepierre P., Wordsworth P., et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36(4):801-808.
19. Vastesaeger N., van der Heijde D., Inman R.D., et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011, 70(6):973-981.
20. Rudwaleit M., Listing J., Brandt J., et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63(6):665-670.
21. Deyo R.A., Weinstein J.N. Low back pain. N Engl J Med 2001, 344(5):363-370.
22. Calin A., Porta J., Fries J.F., et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977, 237(24):2613-2614.
23. Rudwaleit M., Metter A., Listing J., et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006, 54(2):569-578.
24. Sieper J., van der Heijde D., Landewe R., et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis 2009, 68(6):784-788.
25. Rudwaleit M., Sieper J. A case of axial undifferentiated spondyloarthritis diagnosis and management. Nat Clin Pract Rheumatol 2007, 3(5):298-303.
26. Rudwaleit M., Feldtkeller E., Sieper J. Easy assessment of axial spondyloarthritis (early ankylosing spondylitis) at the bedside. Ann Rheum Dis 2006, 65(9):1251-1252.
27. Rudwaleit M., van der Heijde D., Khan M.A., et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004, 63(5):535-543.
28. Brown M.A., Kennedy L.G., MacGregor A.J., et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997, 40(10):1823-1828.
29. Burton P.R., Clayton D.G., Cardon L.R., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007, 39(11):1329-1337.
30. Poddubnyy D.A., Rudwaleit M., Listing J., et al. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 2010, 69(7):1338-1341.
31. Poddubnyy D., Haibel H., Listing J., et al. Baseline radiographic damage, elevated acute phase reactants and cigarette smoking status predict radiographic progression in the spine in early axial spondyloarthritis. Arthritis Rheum 2012, 64(5):1388-1398.
32. van Tubergen A., Heuft-Dorenbosch L., Schulpen G., et al. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality?. Ann Rheum Dis 2003, 62(6):519-525.
33. Rudwaleit M., Jurik A.G., Hermann K.G., et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009, 68(10):1520-1527.
34. Song I.H., Carrasco-Fernandez J., Rudwaleit M., et al. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 2008, 67(11):1535-1540.
35. Klauser A., Halpern E.J., Frauscher F., et al. Inflammatory low back pain: high negative predictive value of contrast-enhanced color Doppler ultrasound in the detection of inflamed sacroiliac joints. Arthritis Rheum 2005, 53(3):440-444.
36. Strobel K., Fischer D.R., Tamborrini G., et al. 18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging 2010, 37(9):1760-1765.
37. D'Agostino M.A., Aegerter P., Bechara K., et al. How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography. Ann Rheum Dis 2011, 70(8):1433-1440.
38. Amor B., Dougados M., Mijiyawa M., et al. Rev Rhum Mal Osteoartic 1990, 57(2):85-89.
39. Dougados M., van der Linden S., Juhlin R., et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34(10):1218-1227.
40. Rudwaleit M., Landewe R., van der Heijde D., et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009, 68(6):770-776.
41. Rudwaleit M., van der Heijde D., Landewe R., et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68(6):777-783.
42. Rudwaleit M., van der Heijde D., Landewe R., et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70(1):25-31.
43. Sieper J., Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 2005, 64(5):659-663.
44. Brandt H.C., Spiller I., Song I.H., et al. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 2007, 66(11):1479-1484.
45. Poddubnyy D., Vahldiek J., Spiller I., et al. Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol 2011, 38(11):2452-2460.
46. Hermann J., Giessauf H., Schaffler G., et al. Early spondyloarthritis: usefulness of clinical screening. Rheumatology (Oxford) 2009, 48(7):812-816.
47. Braun A., Saracbasi E., Grifka J., et al. Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain?. Ann Rheum Dis 2011, 70(10):1782-1787.
48. van der Heijde D., Baraf H.S., Ramos-Remus C., et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005, 52(4):1205-1215.
49. Sieper J., Klopsch T., Richter M., et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008, 67(3):323-329.
50. Wanders A., Heijde D., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52(6):1756-1765.
51. Poddubnyy D., Rudwaleit M., Haibel H., et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012, [Epub ahead of print].
52. Braun J., Zochling J., Baraliakos X., et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006, 65(9):1147-1153.
53. Haibel H., Brandt H.C., Song I.H., et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007, 66(3):419-421.
54. Haibel H., Rudwaleit M., Braun J., et al. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005, 64(1):124-126.
55. Braun J., Bollow M., Seyrekbasan F., et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 1996, 23(4):659-664.
56. van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52(2):582-591.
57. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54(7):2136-2146.
58. Davis J.C., van der Heijde D.M., Braun J., et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005, 64(11):1557-1562.
59. Inman R.D., Davis J.C., Heijde D., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008, 58(11):3402-3412.
60. van der Heijde D., Landewe R., Einstein S., et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58(5):1324-1331.
61. van der Heijde D., Landewe R., Baraliakos X., et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008, 58(10):3063-3070.
62. van der Heijde D., Salonen D., Weissman B.N., et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009, 11(4):R127.